LogoFDA 510(k) Search
K Number
K073145
Device Name
QUANTA LITE H-TTG SCREEN
Manufacturer
INOVA DIAGNOSTICS, INC.
Date Cleared
2008-02-12

(96 days)

Product Code
MVMAUT
Regulation Number
866.5660
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
The QUANTA Lite™ h-tTG Screen is an enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative detection of IgA and IgG antibodies to human tissue transglutaminase (htTG) in human serum. The presence of these antibodies can be used in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of both IgA sufficient and IgA deficient celiac disease as well as dermatitis herpetiformis.
Device Description
Each device contains the following: polystyrene microplate strips with breakaway (12 (1x8) microwells coated with human tissue transglutaminase antigen with holder; high positive, low positive and negative controls (human serum); HRP wash concentrate; HRP sample diluent; HRP IgG and IgA (goat) anti-human conjugate; TMB chromogen; and HRP stop solution (0.344M sulfuric acid).
More Information

K011566, K011570

Not Found

No
The summary describes a standard ELISA kit for detecting antibodies and does not mention any AI or ML components in the device description, intended use, or performance studies.

No
This device is an in-vitro diagnostic (IVD) test used to detect antibodies for diagnostic purposes, not to treat or prevent a disease.

Yes
The device is described as an "enzyme-linked immunosorbent assay (ELISA)" for detecting antibodies, and its intended use is "to aid in the diagnosis of both IgA sufficient and IgA deficient celiac disease as well as dermatitis herpetiformis." This clearly indicates its role in disease diagnosis.

No

The device description clearly lists physical components such as microplate strips, controls, and various chemical solutions, indicating it is a hardware-based diagnostic kit, not software.

Yes, this device is an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use explicitly states it's for the "semi-quantitative detection of IgA and IgG antibodies to human tissue transglutaminase (htTG) in human serum." This involves testing a sample taken from the human body (serum) outside of the body (in vitro) to provide information for diagnosis.
  • Device Description: The components listed (microplate strips, controls, reagents) are typical of an ELISA kit, which is a common type of in vitro diagnostic test.
  • Clinical Context: The intended use also states that the results are used "in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of both IgA sufficient and IgA deficient celiac disease as well as dermatitis herpetiformis." This clearly indicates its role in the diagnostic process.

N/A

Intended Use / Indications for Use

The QUANTA Lite™ h-tTG Screen is an enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative detection of IgA and IgG antibodies to human tissue transglutaminase (htTG) in human serum. The presence of these antibodies can be used in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of both IgA sufficient and IgA deficient celiac disease as well as dermatitis herpetiformis.

Product codes

MVM

Device Description

Each device contains the following: polystyrene microplate strips with breakaway (12 (1x8) microwells coated with human tissue transglutaminase antigen with holder; high positive, low positive and negative controls (human serum); HRP wash concentrate; HRP sample diluent; HRP IgG and IgA (goat) anti-human conjugate; TMB chromogen; and HRP stop solution (0.344M sulfuric acid).

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

For prescription only.

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

1. Analytical performance:
* a. Precision/Reproducibility:
* Intra-assay precision: Nine serum samples tested five times on one kit lot by one operator.
* 4 samples (high concentrations, 32.6-46.8 units) had %CV of 1.2-7.7%.
* 3 samples (close to cut-off, 18.3-22.3 units) had % CV of 2.1-5.8%.
* 2 negative samples (7.7-13.5 units) had %CV of 5.6-7.2%.
* Inter-assay precision: Twelve serum samples tested in duplicate six times for five days on one kit lot by one operator.
* 5 samples (high concentrations, 31.3-49.3 units) had %CV of 2.2-9.3%.
* 3 samples (close to cut-off, 16.0-23.0 units) had % CV of 4.8-11.3%.
* 4 negative samples (5.2-14.5units) had %CV of 6.1-18.4%.
* b. Linearity/assay reportable range: Not applicable.
* Traceability, Stability, Expected values:
* No reference standards for htTG. Controls are in-house prepared with arbitrary units.
* Stability: Expiration date claim is one year.
* d. Detection limit: Not applicable.
* e. Analytical specificity:
* Interference by endogenous substances: No data provided. Avoid grossly hemolyzed, lipemic, icteric, microbially contaminated, heat-treated samples or specimens containing visible particulate.
* Crossreactivity with other autoantibodies: Tested with 44 sera containing other autoantibodies (Chromatin, Centromere, GBM, SS-B, RNP, SCL-70, Jo-1, Sm, SS-A, TPO). All samples were negative (mean 4.6 U/mL, below 20 unit cut-off).
* f. Assay cut-off:
* Established at 20 units from 381 random asymptomatic healthy individuals in the United States.
* Age range: 14-76 years (for 269 samples).
* Gender: 141 male, 128 female subjects (for 269 samples).
* Assay specificity: 97.9% (373/381).
* Mean value of 381 samples: 8.6 units (SD 4.4 units).
* Of 8 positive samples: 6 weak positive (20.3-28.4 units), 1 moderate positive (32.4 units), 1 strong positive (54.9 units, believed to be true celiac).

2. Comparison studies:
* a. Method comparison with predicate device:
* Tested 125 samples from four celiac disease reference labs and 81 normal samples.
* Positive Percent Agreement: 100.0% (52/52).
* Negative Percent Agreement: 97.1% (451/454).
* Overall Agreement: 97.4% (493/506).
* 13 samples were h-tTG Screen positive but negative on predicate IgA/IgG kits (all under 30 units; 3 from celiac patients on GFDs, 2 from 1st-degree relatives, 8 from healthy subjects).
* b. Matrix comparison: Serum is the only recommended matrix.

3. Clinical studies:
* a. Clinical Sensitivity and specificity:
* Evaluated on 517 clinically defined samples.
* Diagnosis groups: 23 Celiacs untreated, 5 Celiac IgA Deficient, 18 Celiac 1st degree relatives, 13 Dermatitis Herpetiformis, 44 Disease Controls, and 414 Healthy individuals.
* Assay sensitivity: 87.8% (36/41).
* Assay specificity: 97.1% (462/476).
* Individual diagnosis sensitivity:
* Celiacs untreated (n=23): 100% (23/23)
* Celiac IgA Deficient (n=5): 80% (4/5)
* Celiacs on Gluten-Free Diet (n=33): 45% (15/33)
* 1st degree relatives (n=18): 22% (4/18)
* Dermatitis Herpetiformis (n=13): 69% (9/13)
* Disease Controls (n=44): 0% (0/44)
* Normals (n=414): 2.4% (10/414)

4. Clinical cut-off: Same as assay cut-off (20 units).

5. Expected values/Reference range: Expected values in the normal population should be negative.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Assay specificity (from cut-off establishment): 97.9% (373/381)
Clinical sensitivity: 87.8% (36/41)
Clinical specificity: 97.1% (462/476)
Positive Percent Agreement (comparison with predicate): 100.0% (52/52)
Negative Percent Agreement (comparison with predicate): 97.1% (451/454)
Overall Agreement (comparison with predicate): 97.4% (493/506)

Predicate Device(s)

K011566, K011570

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 866.5660 Multiple autoantibodies immunological test system.

(a)
Identification. A multiple autoantibodies immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the autoantibodies (antibodies produced against the body's own tissues) in serum and other body fluids. Measurement of multiple autoantibodies aids in the diagnosis of autoimmune disorders (disease produced when the body's own tissues are injured by autoantibodies).(b)
Classification. Class II (performance standards).

0

FEB 1 2 2008

K073/45

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

  • K073145 B. Purpose for Submission: New device C. Measurand: Anti-human tissue transglutaminase (htTG) IgG and IgA antibodies D. Type of Test: Semi-quantitative ELISA E. Applicant: NOVA Diagnostics, Inc. F. Proprietary and Established Names: QUANTA Lite™ h-tTG Screen

G. Regulatory Information:

    1. Regulation section: 21 CFR § 866.5660 Multiple autoantibodies immunological test systems
    1. Classification: Class II

A. 510(k) Number:

    1. Product codes: MVM, Autoantibodies, Endomysial (Tissue Transglutaminase) 4. Panel:
      Immunology 82

H. Intended Use:

    1. Intended use(s):
      The QUANTA Lite™ h-tTG Screen is an enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative detection of IgA and IgG antibodies to human tissue transglutaminase (htTG) in human serum. The presence of these antibodies can be used in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of both IgA sufficient and IgA deficient celiac disease as well as dermatitis herpetiformis
    1. Indication(s) for use:
    • Same as Intended use.

  • Special conditions for use statement(s): 3. For prescription only.

    1. Special instrument requirements: Microplate reader capable of measuring OD at 450 nm (or 650 for dual wavelength readings)

I. Device Description:

Each device contains the following: polystyrene microplate strips with breakaway (12 (1x8) microwells coated with human tissue transglutaminase antigen with holder; high positive, low positive and negative controls (human serum); HRP wash concentrate; HRP sample diluent; HRP IgG and IgA (goat) anti-human conjugate; TMB chromogen; and HRP stop solution (0.344M sulfuric acid).

J. Substantial Equivalence Information:

1

1

    1. Predicate device name(s): QUANTA Lite™ h-tTG IgA
      QUANTA Lite™ h-tTG IgG
  1. Predicate K number(s):
Similarities
ItemNew DevicePredicate Device
QUANTA Lite™ h-
tTG ScreenQUANTA
Lite™ h-tTG
IgA
QUANTA
Lite™ h-tTG
IgG
TechnologyELISASame
AntigenPurified h-tTG antigenSame
MeasurementSemi-quantitativeSame
Assay Platform96 well microtiter plateSame
Sample type and
dilutionSerum at 1:101Same
Sample volume
required5 μLSame
Low Positive, High
positive and
Negative ControlPre-diluted human
serum. Ready to use.Same
DiluentHRP sample diluentSame
HRP Wash
concentrate40XSame
SubstrateTMB ChromogenSame
HRP Stop solution0.344M Sulfuric AcidSame
Assay washing stepTwo stepsSame
Incubation times30-30-30 minutesSame
Spectrophotometric
OD Reading450nm (or 620 for dual
wavelength)Same
Detection MethodColorimetricSame
Cut-off20.0 unitsSame
ItemDevicePredicate
Intended useQUANTA Lite™
h-tTG ScreenQUANTA Lite™
h-tTG IgAQUANTA Lite™
h-tTG IgG
For the semi-
quantitative
detection of IgA
and IgG antibodies
to human tissue
transglutaminaseFor the semi-
quantitative
detection of IgA
antibodies to
tissue
transglutaminaseFor the semi-
quantitative
detection IgG
antibodies to
tissue
transglutaminase

2

ItemDevicePredicate
(htTG) in human serum.(endomysium) in human serum.
Indications for UseAid in the diagnosis of both IgA sufficient and IgA deficient celiac disease as well as dermatitis herpetiformisAid in the diagnosis of certain gluten sensitive enteropathies such as celiac disease and dermatitis herpetiformis
Aid in the diagnosis of certain gluten sensitive enteropathies such as celiac disease and dermatitis herpetiformis. This test is intended for providing added sensitivity when testing IgA deficient patients
Enzyme ConjugateHorseradish Peroxidase, Goat anti-human IgA and IgGHorseradish Peroxidase, Goat anti-human IgA
Horseradish Peroxidase, Goat anti-human IgG
Result InterpretationNeg = $$ 30
Neg = $$ 30

K. Standard/Guidance Document Referenced (if applicable):

CLSI (NCCLS) H18-A3 Sample storage conditions and CLSI (NCCLS) C24-A3 Appropriate Quality Control Practices.

L. Test Principle:

Native human tissue transglutaminase is bound to the wells of a polystyrene microwell plate under conditions that will preserve the antigen in its native state. Prediluted controls and diluted patient sera are added to separate wells, allowing any htTG IgA or IgG antibodies present to bind to the immobilized antigen. Unbound sample is washed away and an enzyme labeled anti-human IgA and IgG conjugate is added to each well. A second incubation allows the enzyme labeled anti-human IgA and IgG to bind to any patient antibodies, which have become attached to the microwells. After washing away any unbound enzyme labeled anti-human IgA and IgG, the remaining enzyme activity is measured by adding a chromogenic substrate and measuring the intensity of the color that develops. The assay can be evaluated spectrophotometrically by measuring and comparing the color intensity that develops in the patient wells with the color in the control wells

M. Performance Characteristics (if/when applicable):

    1. Analytical performance:
    • a. Precision/Reproducibility:

3

The intra-assay precision was determined by testing nine serum samples five times on one kit lot by one operator. Results showed that 4 samples with high anti-h-tTG concentrations (32.6-46.8 units) had %CV of 1.2-7.7%. 3 samples close to the cut-off (18.3-22.3 units) had % CV of 2.1-5.8% and 2 negative samples (7.7-13.5 units) had %CV of 5.6-7.2% (see table below).

Sample114.000 - 14.00 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1.0 - 1
Mean unitsleast and the first of the first the first the first the first the first the first the first the first the first the first the first the first the first the first the finited
19 11
  • Canada Career of Concession & An | | | - | | | | 1 |
    | CT | | . . | | œ
  • 9 had | . . | | | |
    | C
    10 | . | | | | 1 | A B AR A C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C | CONTRACTOR A CARREN & CLANDLE & CONTRACT AND | 1
    C |

Intra-assay Performance of QUANTA Lite™ h-tTG Screen ELISA

The inter-assay precision was determined by testing twelve serum samples in duplicate six times for five days on one kit lot by one operator. Results showed that 5 samples with high anti-h-tTG concentrations (31.3-49.3 units) had %CV of 2.2-9.3%, 3 samples close to the cut-off (16.0-23.0 units) had % CV of 4.8-11.3% and 4 negative samples (5.2-14.5units) had %CV of 6.1-18.4% (see table below).

Inter-assay Performance for QUANTA Lite™ h-tTG Screen ELISA

| Status Collection Comparis Comparis Comparis Comparis Comparis Comparis Comparis Comparis Comparis Comparis Comparis Comparis Comparis Comparis Comparis Comparis Comparis Com
Sample

---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
-------------------------------------
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Mean unitsﻟ
And And Andrew States of the State The Way0
ﺮﻳﺔ
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------1
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------1
را ۽ اس ساﮨﺎ ﮨﮯ ﺍﻭﺭ ﺍﯾﮏ ﮐﯿﺎ ﮐﮧ ﺍﯾﮏ ﮐﮯ ﺍﯾﮏ ﺭﮨﺎﺋﺸﯽ ﮨﮯ ﺍﻭﺭ ﺍﺱ ﮐﮯ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍﯾﮏ ﺍ

  • No Amou La | AMAGARA
    1000 100 | | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
    1
    . VIN | No. of Confinence | ﺎ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
    | CIT
    A RESIDENT CAR CLEAN | | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | Free on 2 and 1 east 1 personal | 1.1 | N ROOM BOOK I ---------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------- | ------------------------------------- | Bearing Line La La |
    | 0 1 2 2 0 / | STATISTICS AND THE CONSULT OF CONSULT OF CONSULT OF CONSULT OF CONSULT OF CONSULT OF CONSULT OF CONSULT OF CONSULT OF CONSULT OF CONSULT OF CONSULT OF CONSULT OF CONSULT OF C | A 4 Am
    Acres of the property of | سنڌ ۾ اسڪ | | 19.4 | And Analy | Age Access of Canadian Cases of Canadian Career of Children | | NO. OHIO A LA BE BU BU
    1 | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
    ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ﺮ |

  • b. Linearity/assay reportable range: Not applicable.

  • Traceability, Stability, Expected values (controls, calibrators, or methods): C. There are no reference standards for htTG. The positive and negative controls are prepared in-house and arbitrary units are assigned during the development process.

Stability: The expiration date claim is one year for the QUANTA Lite™ htTG Screen.

  • d. Detection limit:
    Not applicable.

  • Analytical specificity: e.
    Interference by endogenous substances: No data provided. The package insert states that grossly hemolyzed, lipemic, icteric, microbially contaminated, heattreated samples or specimens containing visible particulate should be avoided in this assay.

Crossreactivity with other autoantibodies: The QUANTA Lite™ h-tTG Screen was tested with 44 sera containing other autoantibodies specific for:

Chromatin (4), Centromere (4), GBM (4), SS-B (4), RNP (5), SCL-70 (6), Jo-1 (5), Sm (4), SS-A (4), and TPO (4). All samples were negative with the QUANTA Lite"" h-tTG Screen with a mean value of 4.6 U/mL which is below

the 20 unit cut-off.

4

  • f. Assav cut-off:
    The assay cut-off of 20 units for the assay was established from 381 random asymptomatic healthy individuals residing in the United States. Age and gender were available for 269 samples and unavailable for the remaining 112 samples. The age ranges were 14-76 years and included 141 male subjects and 128 female subjects. The assay specificity was 97.9% (373/381). The mean value of 381 samples was 8.6 units. The standard deviation (SD) of the samples was 4.4 units. The mean value was 2.5SDs below the cut-off value of 20 units. Of the 8 positive samples, six were weak positive with values from 20.3 - 28.4 units; one moderate positive value was 32.4 units and one strong positive value was 54.9 units which was believed to be from a true celiac patient based on a positive IgA anti-h-tTG result of 72.4 units.

    1. Comparison studies:
    • a. Method comparison with predicate device:

Testing was performed on 125 samples from four celiac disease reference labs and 81 normal samples. The Positive Percent Agreement was 100.0% (52/52); the Negative Percent Agreement was 97.1% (451/454) and the Overall Agreement was 97.4% (493/506).

QUANTA Lite TM h-tTG IgA or IgG
PositiveNegativeTotal
QUANTA
LiteTM h-tTG
ScreenPositive5213*65
QUANTA
LiteTM h-tTG
ScreenNegative0441441
QUANTA
LiteTM h-tTG
ScreenTotal52454506
    • Of the 13 samples found to be h-tTG Screen positive, yet negative on both h-tTG IgA and h-tTG IgG kits, 3 from celiac patients on GFDs, two from 1st degree relatives, and eight from apparently healthy subjects. All 13 samples had values under 30 units.
  • b. Matrix comparison:

Serum is the only recommended matrix.

    1. Clinical studies:
    • Clinical Sensitivity and specificity: a.

The clinical sensitivity and specificity study were evaluated on 517 clinically defined samples from patients with the following diagnosis: 23 Celiacs untreated, 5 Celiac IgA Deficient, 18 Celiac 1st degree relatives, 13 Dermatitis Herpetiformis, 44 Disease Controls, and 414 Healthy individuals. The QUANTA Lite™ h-tTG Screen assay sensitivity and specificity were 87.8% (36/41) and 97.1% (462/476) respectively (refer to table below).

Diagnosis
Positives
(Celiacs untreated
and IgA deficient)Negative
(1st degree relatives, Disease
Controls and Healthy Controls)Totals
QUANTA
LITE™ h-tTG
ScreenPositive361450
QUANTA
LITE™ h-tTG
ScreenNegative5462467
QUANTA
LITE™ h-tTG
ScreenTotal41476517

5

In addition, a summary of the results for the individual diagnosis is listed below:

DiagnosisnPositive h-tTG Screen% Sensitivity
Patient
GroupsCeliacs untreated2323100%
Celiac IgA Deficient5480%
Celiacs on Gluten-Free Diet33*1545%
1st degree relatives18422%
Dermatitis Herpetiformis13969%
Disease Controls4400%
Normals41410**2.4%

*33 GFD Celiacs were excluded from the previous sensitivity/ specificity table.

** 1 of the 10 positives was found to be positive on individual h-tTG ELISA assays and also positive for tTG by fluid phase RIA.

  • b. Other clinical supportive data (when a. is not applicable): Not applicable.
    1. Clinical cut-off:

Same as assay cut-off.

    1. Expected values/Reference range:
      Expected values in the normal population should be negative.

N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.

6

DEPARTMENT OF HEALTH & HUMAN SERVICES

Image /page/6/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which is a staff with two snakes coiled around it, and the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged in a circle around the symbol. The caduceus is a common symbol associated with healthcare and medicine.

Public Health Service

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

FEB 1 2 2008

INOVA Diagnostics, Inc. c/o Mr. Joseph Phillips Group Lead Development 9900 Old Grove Rd. San Diego, CA 92131-1638

Re: K073145

Trade/Device Name: QUANTA Lite™ h-tTG Screen Regulation Number: 21 CFR 866.5660 Regulation Name: Multiple autoantibodies immunological test system Regulatory Class: Class II Product Code: MVM Dated: February 5, 2008 Received: February 6, 2008

Dear Mr. Myers:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The

7

Page 2 -

FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers. International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Robert H. Becker

Robert L. Becker, Jr., M.D., Ph.D. Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

8

Indications for Use

510(k) Number (if known): K073145

Device Name: QUANTA Lite™ h-tTG Screen

Indications for Use:

The QUANTA Lite™ h-tTG Screen is an enzyme-linked immunosorbent assay (ELISA) for the semi-quantitative detection of IgA and IgG antibodies to human tissue transglutaminase (h-tTG) in human serum. The presence of these antibodies can be used in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of both IgA sufficient and IgA deficient celiac disease as well as dermatitis herpetiformis.

Prescription Use ਮ (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Marci M Chan
Division Sign-Off

Division sign on

Office of in Vitro Diagnostic Device Evaluation and Safety Page 1 of

510kK073/45